Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion InjuryPodsawee Mongkolpathumrat, Sarawut Kumphune|Biomedicines|2021Cited by 14
Cardiac endothelial ischemia/reperfusion injury-derived protein damage-associated molecular patterns disrupt the integrity of the endothelial barrierSarawut Kumphune, Nitirut Nernpermpisooth|Heliyon|2024Cited by 11
Bioactive secretory leukocyte protease inhibitor (SLPI)-derived short peptides (SDSPs) attenuate LPS-induced inflammatory responses in macrophagesWattanased Jarisarapurin, Sarawut Kumphune|Scientific Reports|2026Cited by 0